Professor David W. Denning

Dr. Denning is an infectious diseases clinician with expertise in fungal diseases. He serves as the Chief Executive of the Global Action Fund for Fungal infections (GAFFI) and Professor of Infectious Diseases and Global Health at the University of Manchester, UK. Dr Denning manages the National Aspergillosis Centre, Manchester, a referral centre in the UK for all patients with chronic pulmonary aspergillosis. His current academic interests are chronic and allergic pulmonary fungal disease, the global burden of fungal infection, resistance in Aspergillus and getting new antifungals developed. He has published extensively (>550 academic papers) and has a citation H-index of 114. He leads LIFE (Leading Internal Fungal Education (, which is focused on improving patient outcomes through online education. He is the Chief Executive of the Global Action Fund for Fungal Infections (, based in Switzerland and the UK which advocates for access to fungal diagnostics and antifungal therapies. He is the founder of 2 biotechnology companies – F2G Ltd (antifungal drug discovery and development in phase 2) and Myconostica Ltd (now Lab21) for molecular diagnostic tests for fungi.